Manitoba's Immunization Program: Vaccines Offered Free-of-Charge
(Eligibility Criteria for Publicly-Funded Vaccines)

Effective as of June 2017

Vaccines listed here are provided free-of-charge to individuals who are registered with Manitoba Health, Seniors and Active Living (MHSAL) and for those who are part-way through an immunization series started in another province or territory as part of a publicly-funded program (pending product availability). Uninsured visitors will be provided vaccines free-of-charge if there is an immediate public health need, as determined in consultation with a health care provider.

MHSAL covers all costs associated with administering a publicly-funded vaccine (e.g. physician fees).   

Publicly-funded vaccines can only be obtained from the Provincial Vaccine Warehouse by an immunization provider (or delegate) who is registered with MHSAL. Immunization providers can order vaccines by completing MHSAL’s Vaccines and Biologics Order Form. Publicly-funded vaccines are provided to health care providers for the sole purpose of administering MHSAL’s Immunization Program.

Individuals who do not receive a publicly-funded vaccine when it is first recommended are eligible to receive the vaccine at a later time. This is commonly referred to as, ‘once eligible, always eligible.’

Vaccines for TRAVEL, OCCUPATIONAL HEALTH or EDUCATIONAL PURPOSES are not provided by MHSAL (with the exception of the following vaccines for occupational health purposes: rabies vaccine; mumps, measles and rubella vaccine; and seasonal influenza vaccine; please refer to the vaccine-specific sections below for more information).

MHSAL does not reimburse individuals who pay out-of-pocket for a vaccine that is offered free-of-charge.

Additional doses of a vaccine that are given outside of MHSAL's publicly-funded, recommended immunization series are provided free-of-charge to individuals with certain high-risk medical conditions, as well as to individuals with an inadequate immune response post-immunization (one additional dose), as determined by a health care provider.

For more detailed information about vaccine schedules, please refer to parts 3 and 4 of the Canadian Immunization Guide (CIG).

The list of vaccines offered free-of-charge (as per below) are subject to change as determined by MHSAL. Check MHSAL's Recommended Immunization Schedule for Infants, Children and Adults for more information about when routine immunizations should be given.

Vaccines provided free-of-charge for outbreak management and control of communicable diseases are listed in MHSAL's Communicable Disease Management ProtocolsManual and/or as determined by a provincial Medical Officer of Health.


Diphtheria, Tetanus Toxoid, acellular Pertussis, Inactivated Polio, Haemophilus influenza type b - paediatric (DTaP-IPV-Hib)
  • All children from 2 months of age to < 7 years of age
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)
  • Note: DTaP-IPV was previously used in children from 4 years of age to < 7 years who had been not previously immunized as part of their primary series. DTaP-IPV is no longer available for use in Canada once current stock is depleted. DTaP-IPV-Hib is to be used in its place. Please refer to the Recommended Immunization Schedules for those Not Previously Immunized. (https://www.gov.mb.ca/health/publichealth/cdc/div/not.html)
Haemophilus influenza type b (Hib)
  • Children from 2 months of age to < 5 years of age (up to 59 months).
  • Individuals ≥ 5 years of age with at least one of the following high-risk medical conditions are eligible to receive 1 dose regardless of Hib immunization history, at least one year after any previous dose:
    • Asplenia or hyposplenism
    • Cochlear implant recipients
    • Congenital immune deficiencies (B cell deficiency, T cell mixed defects, phagocytic and neutrophil disorders, complement deficiency)
    • Hemoglobinopathies
    • HIV-infection
    • Hematopoietic stem cell transplant recipients and solid organ transplant recipients (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)
Hepatitis A (HA)
  • Individuals ≥ 6 months with at least one of the following high-risk medical conditions are eligible to receive 2 doses (refer to Table 1: Dosages and Schedules for Hepatitis A-containing Vaccines of the Canadian Immunization Guide):
    • Chronic renal disease or undergoing dialysis
    • Chronic liver disease including people infected with hepatitis C and chronic hepatitis B carriers
    • Non-malignant hematologic disorders including repeated replacement of plasma-derived clotting factors
    • HIV-infection
    • Hematopoietic stem cell transplantation (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
    • Solid organ transplant candidates and recipients with chronic liver diseases (prior to transplant or 6 months post-transplant)
    • Congenital immune deficiencies (B cell deficiency, T cell mixed defects, phagocytic and neutrophil disorders, complement deficiency)
  • Individuals with life-style risks for infection, including people engaging in illicit drug use and men having sex with men (MSM).
Hepatitis B (HB)
  • All children born on or after January 1st 2006 in Grade 6 (school-based program) are eligible to receive 2 doses of: Recombivax HB® 1.0mL at 0, 4-6 months OR Engerix®-B 1.0mL at 0, 6 months.
  • Individuals born between 1989 and 2005 who missed the vaccine in Grade 4 (school-based program) are eligible for up to 4 doses; 3 or 4 doses are recommended for individuals 16 years of age and older.*
  • Individuals of any age with at least one of the following high-risk medical conditions are eligible to receive 3 or 4 doses:*
    • Chronic liver disease from any cause, including persons infected with hepatitis C.
    • Hemophiliacs and other people receiving repeated infusions of blood or blood products.
    • Chronic renal disease or undergoing chronic dialysis (hemodialysis or peritoneal dialysis).
    • Congenital immune deficiencies (B cell deficiency, T cell mixed defects, phagocytic and neutrophil disorders, complement deficiency).
    • HIV-infection.
    • Hematopoietic stem cell transplant recipient (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule) or awaiting solid organ transplant.
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)
  • Inmates of correctional facilities.*
  • Residents of institutions for the developmentally challenged.*
  • Individuals with lifestyle risks for infection, including people engaging in illicit drug use, men having sex with men (MSM) and those who engage in other risky sexual practices.*
  • Premature and/or full-term infants of mothers who are hepatitis B surface antigen (HBsAg) positive or unknown HBsAg status are eligible for up to 4 doses.**

*Refer to Table 3: Recommended Dosages and Schedules for Hepatitis B-Containing Vaccines of the Canadian Immunization Guide for product-specific recommendations by age/medical condition.

**Refer to Table 3: Recommended Dosages and Schedules for Hepatitis B-Containing Vaccines as well as Table 4: Hepatitis B Recommendations for Premature Infants Weighing less than 2,000 grams, by Maternal Hepatitis B Surface Antigen (HBsAg) Status of the Canadian Immunization Guide for vaccine dosage, interval and schedule recommendations.

Hepatitis A & B (HAHB)
  • HAHB may be made available to individuals meeting the criteria for both hepatitis A and B immunizations, provided the individual is still susceptible to both hepatitis A and hepatitis B viruses (i.e. no prior infection with hepatitis A or B, no prior immunization with hepatitis A or B).
Human Papillomavirus (HPV)
  • Healthy females born on or after January 1, 1997 are eligible to receive the HPV vaccine, routinely provided in school-based programs in Grade 6.
  • Effective September 2016, healthy males born on or after January 1, 2002 are eligible for school-based programs in Grade 6 as well as in Grade 8 or 9 (3 year catch-up program).
  • For females and males under 15 years of age, 2 doses are recommended. For those who missed the school-based program, a 3 dose schedule is recommended, unless the first dose of vaccine was administered before the age of 15.
  • Immunocompetent HIV-infected and/or immunocompromised females (born during or after 1997) and males (born during or after 2002) are eligible to receive 3 doses. Immunocompromised conditions include:
  • Females born between 1986 and 1996 with increased risk of HPV infection, who started the vaccine series before March 31, 2014, are eligible to receive 3 doses.
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)
Inactivated Polio Virus (IPV)
  • Children from 7 years of age and < 18 years of age, not immunized in early infancy.
  • Hematopoietic stem cell transplant recipients (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule). 
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)
Measles, Mumps, Rubella (MMR)
  • Those born before 1970 are considered immune and do not require MMR vaccine.
  • Non-immune Manitobans born between 1970 and 1984 are eligible for one (1) dose of MMR vaccine.
  • Those born during or after 1985 are eligible for 2 doses of MMR vaccine.
  • All children ≥ 12 months of age are eligible to receive 2 doses.
  • Non-immune health care workers, regardless of age, are eligible for 2 doses of MMR vaccine.
  • Non-immune students born before 1970 are eligible for 1 dose; students born in 1970 or later are eligible for 2 doses of MMR vaccine.
  • Adolescents and adults (regardless of year of birth) without proof of immunity for rubella are eligible for 1 dose of MMR vaccine.
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have been provided a CCMB directed Immunization Schedule.

Susceptibility and Immunity to Rubella: www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-20-rubella-vaccine.html

  • Individuals who have one or more of the following are considered immune to rubella. Individuals who do not have ANY of the following are considered susceptible to rubella:
    • Documented evidence of immunization with a rubella-containing vaccine on or after the first birthday
    • A history of laboratory confirmed rubella infection
    • Laboratory evidence of immunity
Measles, Mumps, Rubella, Varicella (MMRV)
  • Individuals 12 years of age and under meeting the eligibility criteria for both mumps, measles, and rubella (MMR) and varicella (Var) immunizations. 
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who  have been provided a CCMB directed Immunization Schedule.
Meningococcal Conjugate Group C (Men-C-C)
  • All children in Grade 4 (school-based program) born between 1995 and 2007 are eligible for one dose, regardless of Men-C-C immunization history.
  • All children born on or after January 1, 2008 are eligible to receive 2 doses at 12 months of age and in Grade 6 (school-based program).
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)
Meningococcal Conjugate (Men-C-ACWY-135)
  • Individuals with at least one of the following high-risk medical conditions:
    • Functional or anatomic asplenia
    • Complement, properdin, factor D or primary antibody deficiency
    • Persons with acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab (Soliris™)
    • Certain genetic risk factors (e.g. polymorphisms in the genes for mannose-binding lectin and tumor necrosis factor)
    • Human immunodeficiency (HIV), especially if it is congenitally acquired
    • Hematopoietic stem cell transplantation (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
    • Solid organ transplantation †
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)

† For the recommended dosing schedule, see the Canadian Immunization Guide (CIG) at: www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines.html?page=13

  • Two to four primary doses are required, depending on the age at first dose, and a booster dose is recommended every five years:
Age at series initiation # of doses Schedule
2 to 11 months 3+1 1st dose
2nd dose, 8 weeks after 1st dose
3rd dose, 8 weeks after 2nd dose
4th dose, 8 weeks after 3rd dose and at age ≥12 months*
12 months of age and older 2 1st dose
2nd dose, 8 weeks after 1st dose (minimum intreval is 4 weeks)*

*A booster dose is recommended every 5 years.

Meningococcal Type B (4CMenB)
  • Individuals 2 months to ≤17 years of age with at least one of the following high-risk medical conditions:
    • anatomic or functional asplenia (including sickle cell disease)
    • congenital complement, properdin, factor D or primary antibody deficiencies
    • acquired complement deficiencies
    • human immunodeficiency virus (HIV)
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
      1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
      2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)
  • Two to four doses are required, depending on the age at first dose:
Age at series initiation # of doses Schedule
2 to 5 months 3+1 1st dose
2nd dose, 2 months after 1st dose
3rd dose, 2 months after 2nd dose
4th dose (booster), between 12 and 23 months of age (as early as possible in the second year of life is preferred) and at least 2 months after 3rd dose
6 to 11 months 3 1st dose
2nd dose, 2 months after 1st dose
3rd dose, at least 2 months after 2nd dose and ≥12 months of age
12 months to 10 years 2 1st dose
2nd dose, 2 months after 1st dose
11 to 17 years 2 1st dose
2nd dose, 1 months after 1st dose

For information on outbreak control, call the regional Medical Officer of Health (MOH).

Pneumococcal Conjugate (Pneu-C-13)
  • Children 2 months to ≤ 59 months of age are eligible to receive 3 doses (2, 4 and 12 months of age)*
  • Children 2 months to ≤ 59 months of age living in First Nations communities are eligible to receive 4 doses (2, 4, 6 and 18 months of age)*
  • Children up to ≤ 59 months of age who received the 7 valent pneumococcal vaccine (Pneu-C-7) series are eligible to receive 1 dose of Pneu-C-13
  • Children 2 months to ≤ 59 months of age with at least one of the following high risk medical conditions are eligible to receive 4 doses (2, 4, 6 and 18 months of age)*:
    • Chronic cerebral spinal fluid (CSF) leak
    • Chronic neurologic condition that may impair clearance of oral secretions
    • Cochlear implants (including those children who are to receive implants)
    • Chronic cardiac or pulmonary disease
    • Diabetes mellitus
    • Asplenia (functional or anatomic)
    • Hemoglobinopathies
    • Congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions
    • Hematopoietic stem cell transplant recipient (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
    • HIV infection
    • Immunosuppressive therapy including use of long term corticosteroids, post-organ transplant therapy, and certain anti-rheumatic drugs
    • Chronic kidney disease, including nephrotic syndrome
    • Chronic liver disease (including hepatic cirrhosis due to any cause)
    • Solid organ or islet transplant (candidate or recipient)
  • Individuals 60 months of age and older with the following high risk medical conditions are eligible to receive doses as described:
    • Hematopoietic stem cell transplant recipients, as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule.
    • Individuals with human immunodeficiency virus (HIV) and/or solid organ transplant recipients are eligible to receive 1 dose of Pneu-C-13 followed 8 weeks later by one dose of pneumococcal polysaccharide (Pneu-P-23). The Pneu-C-13 dose should be administered at least one year after any previous dose of Pneu-P-23, and, a 5 year interval between first dose of Pneu-P-23 and a single lifetime booster dose of Pneu-P-23 is recommended.
  • Patients 2 months of age and older currently under the care of a haematologist or oncologist from Cancer Care Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)

* For late or incomplete dosing schedules, please see the Canadian Immunization Guide

Pneumococcal Polysaccharide (Pneu-P-23)
  • All individuals ≥ 65 years of age are eligible to receive 1 dose.
  • All residents of a personal care home or a long-term care facility are eligible to receive 1 dose.
  • Individuals from 2 to 65 years of age with the following high-risk medical conditions are eligible to receive 1 dose:
    • Chronic cerebral spinal fluid (CSF) leak
    • Cochlear implants (including those children who are to receive implants)
    • Chronic cardiac or pulmonary disease
    • Diabetes mellitus
    • Chronic kidney disease
    • Chronic liver disease (including hepatic cirrhosis due to any cause)
    • Hemoglobinopathies
    • Congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions
    • Asplenia (functional or anatomic)
    • Immunocompromising therapy including use of long-term corticosteroids, post-organ transplant therapy, and certain anti-rheumatic drugs
    • HIV infection
    • Hematopoietic stem cell transplant recipient (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
    • Solid organ or islet transplant (candidate or recipient)
    • Chronic neurologic condition that may impair clearance of oral secretions
    • Nephrotic syndrome
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
      1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
      2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)
  • All individuals with one or more of the following lifestyle factors are eligible to receive 1 dose:
    • persons with alcoholism
    • persons who are homeless, or
    • persons who are illicit drug users.
  • One lifetime re-immunization after 5 years is recommended for the following individuals at highest risk for invasive pneumococcal disease (IPD):
    • Asplenia (functional or anatomic)
    • Sickle cell disease
    • Hepatic cirrhosis
    • Chronic renal failure
    • Nephrotic syndrome
    • HIV infection
    • Immunosuppression related to disease or therapy †

† For a list of patients eligible under this category, see the Canadian Immunization Guide at: www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations.html?page=8

Rabies Vaccine
  • Individuals with occupational risks (including those completing post-secondary practicum) as follows:
    • veterinarians and veterinarian assistants
    • animal health technologists, veterinary technologists, veterinary office assistants
    • taxidermists, trappers, spelunkers
    • individuals working with injured wildlife
    • conservation officers, park rangers, animal control officers
    • laboratory and field personnel working with rabies
    • zoologists or other individuals working in rabies endemic countries
Rotavirus (Rota)
  • All children born on or after March 1, 2014.
  • The first dose should be given no earlier than 6 weeks of age and before 15 weeks of age.
  • The administration of both doses must be completed by 8 months of age. There should be at least 4 weeks between doses.
Seasonal Influenza Vaccine
Tetanus and Diphtheria (Td)
  • All individuals ≥ 7 years of age, every 10 years.
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)
Tetanus, Diphtheria and acellular Pertussis (Tdap)
  • Individuals at 14 to 16 years of age (Grade 8 or 9 school-based program).
  • Individuals who missed the vaccine in Grade 8 or 9 and are born on or after January 1, 1989.
  • Adults who are due for a Td booster and have not previously received a pertussis-containing vaccine in adulthood*.
  • Primary caregivers of a newborn infant up to 6 months of age who have not previously received a pertussis-containing vaccine in adulthood*.
  • Pregnant women ≥ 26 weeks of pregnancy who have not received a dose of a pertussis-containing vaccine in adulthood.
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)

* There is no minimum interval between the Td and Tdap vaccine.

Tetanus, Diphtheria, acellular Pertussis, Inactivated Polio (Tdap-IPV)
  • All children from 4 years of age to < 7 years of age as their pre-school booster. For those 7-18 years of age and not previously immunized please refer to the Recommended Immunization Schedules for those Not Previously Immunized. (https://www.gov.mb.ca/health/publichealth/cdc/div/not.html).
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Patients who are hypo- or asplenic (Sickle Cell Disease, etc.)
Diphtheria, Tetanus. acellular Pertussis, Inactivated Polio (DTaP-IPV)
  • DTaP-IPV is no longer available in Canada once current stock is depleted. It was used in children from 4 years of age to < 7 years who were not previously immunized as part of their primary series. DTaP-IPV-Hib is being used in its place. Please refer to the Recommended Immunization Schedules for those Not Previously Immunized. (www.gov.mb.ca/health/publichealth/cdc/div/not.html)
Varicella (Var)
  • Individuals born between January 1st,  1995 and December 31, 2007 are eligible to receive one dose of varicella vaccine.
  • All children born on or after January 1st, 2008 are eligible to receive two doses of varicella vaccine at 12 months and 4 to 6 years of age.
  • Susceptible individuals with at least one of the following high-risk medical conditions are eligible to receive 2 doses of varicella vaccine (minimum interval between doses is 6 weeks):
    • Children and adolescents receiving chronic salicylate therapy (acetylsalicylic acid)
    • HIV-infected people who are not severely immunocompromised (CD4 cell count ≥ 200 x 106/L and CD4 percentage ≥ 15%)
    • Asplenia (functional or anatomic)
    • Chronic renal disease or undergoing dialysis*
    • Cystic fibrosis*
    • Pre-solid organ transplant (with the second dose given at least 4 weeks prior to transplant)*
    • Hematopoietic stem cell transplant recipients (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have been provided a CCMB directed Immunization Schedule.

*Minimum 3 months between doses.

Communicable Disease Control (CDC)
Public Health
Manitoba Health, Seniors and Active Living
4th Floor - 300 Carlton St.
Winnipeg MB  R3B 3M9  CANADA
Phone: 204-788-6737
Fax: 204-948-2190